BioSpace News Archive

Pharm Country

Dose Escalation in Liver Cancer Study with ADP-A2AFP (AFP) SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 (MAGE-A10) Lung Cancer Study after Favorable Safety Reviews

Adaptimmune Therapeutics plc today announced that the Safety Review Committee (SRC) has endorsed dose escalation in the ongoing ADP-A2AFP (AFP) study in patients with hepatocellular carcinoma (liver cancer) to the second dose cohort.

January 8, 2019
·
5 min read
Drug Development

After Announcing a New CEO, UroGen Touts Positive Phase III Data for Urothelial Cancer

UroGen Pharma, based in New York, announced positive topline results from its Phase III OLYMPUS clinical trial. The trial evaluated UGN-101 (mitomycin gel) for instillation for the non-surgical treatment of low-grade upper tract urothelial cancer (UTUC).

January 8, 2019
·
2 min read
·
Mark Terry
Business

Day One of JPM Brings Excitement and Promise for a New Year in Biotech and Pharma

Biotech and pharma companies came roaring out of the gate on the first day of the annual J.P. Morgan Healthcare Conference with big deals, expansions and promises of growth and pipeline sustainability.

January 8, 2019
·
3 min read
·
Alex Keown
Why 55% of Life Sciences Professionals Aren’t Happy at Work

What is your current level of satisfaction with your job? Are you content and excited to go to work each day? Or, do you dread getting out of bed in the morning on weekdays? BioSpace recently polled an audience of professionals and asked, “Are you happy with your current life sciences job?”

January 8, 2019
·
3 min read
·
Porschia Parker
Drug Development

With Likely Approvals on the Way, Bluebird Bio Offers up Pricing Strategy for Gene Therapy

For a moment, simply contemplate the possible price: $2.1 million for a drug. It’s not just any drug, however. Cambridge, Mass.-based bluebird bio’s LentiGlobin is a gene therapy being evaluated for transfusion-dependent ß-thalassemia.

January 8, 2019
·
4 min read
·
Mark Terry
FDA

FDA Approves Record-Breaking 59 Novel Drugs in 2018

Over the course of 2018, the FDA approved 59 different novel drugs that range for the treatment of various cancers, chronic obstructive pulmonary disease (COPD), traveler’s diarrhea, migraine headaches and more.

January 8, 2019
·
3 min read
·
Alex Keown
Job Trends

Reports: FDA Intends to Establish a New Office to Improve Review Process of New Drugs

According to reports, FDA Commissioner Scott Gottlieb will outline the formation of the Office of Drug Evaluation Sciences, a 52-member group, during his talk at the J.P. Morgan Healthcare Conference in San Francisco later today.

January 8, 2019
·
2 min read
·
Alex Keown
Policy

M&A May Be the Legacy of the Trump Tax Cuts for Pharma

Federal corporate tax cuts that were framed as a way to give a boost to employment across the United States have been more beneficial to companies and shareholders than the average worker or consumer, a new report issued by the advocacy group Americans for Tax Fairness shows.

January 8, 2019
·
3 min read
·
Alex Keown
Deals

It’s a Wrap! Takeda-Shire Merger Is a Done Deal, Making Takeda the Largest Mass. Biotech Employer

Last year’s sole mega-deal, the acquisition of Dublin-based Shire by Japan-based Takeda Pharmaceutical is finally closed. Takeda, 237 years old, is now a top 10 international drug company.

January 8, 2019
·
3 min read
·
Mark Terry
Policy

Class Action Lawsuit Aims to Halt GSK Acquisition of Tesaro

Yesterday, shareholders filed for a class action lawsuit against Tesaro in Delaware federal court, alleging that the merger is based on misleading financial analyses filed with the U.S. Securities and Exchange Commission (SEC).

January 8, 2019
·
2 min read
·
Mark Terry